Position of the Transparency Council – Luxturna (voretigene neparvovec)

At its meeting on 18 November 2024, the Transparency Council adopted position No. on the evaluation of the drug Luxturna (voretigene neparvovec) under the drug program: “Treatment for Leber congenital blindness (LCA) with biallelic mutation of the RPE65 gene (ICD-10: H35.5)”

Publication of the position >>